Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: LocalMed

This article was originally published in The Gray Sheet

Executive Summary

LocalMed: Files investigational device exemption with FDA for its PerfusaSleeve device "which converts an ordinary angioplasty catheter into a perfusion balloon," the company says in a Feb. 8 release. Using the over-the-balloon technology employed in LocalMed's InfusaSleeve drug delivery catheter, cleared via 510(k) in October 1994 ("The Gray Sheet" Oct. 31, 1994, p. 3), PerfusaSleeve "aligns with the balloon and permits blood to flow during angioplasty procedures by routing it around the angioplasty balloon." The blood enters "perfusion channels upstream from the balloon and exits through ports distal to the balloon," LocalMed explains...

You may also be interested in...

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.

Medtech Industry Favorite Wins Seat On Powerful House E&C Committee

As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts